Impact Of RA Therapy Compliance On Patient-Reported Outcomes

Pfizer

Status: Completed

Conditions: Rheumatoid Arthritis

Treatments: Drug: biodmards; Drug: tDMARDs

Study type: Observational

Funder types: Industry

Identifiers

NCT01438892

A3921144

Details and patient eligibility

About

Several observational studies have evaluated the comparative treatment costs associated with each agent, particularly those within the anti-TNF class, but few have evaluated the impact of therapy compliance, persistence, treatment patterns on patient reported outcomes, healthcare utilization and costs, using a provider database. This study is designed to fill in this information gap.

Full description

Cohort observational

Enrollment: 396 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adults with moderate to severe RA who are currently using a DMARD

Exclusion criteria

• Psoriatic Arthritis (PsA), Psoriasis (PsO), SSystemic Lupus Erythematosus (SLE), Non-Disease modifying anti-rheumatic disease (non-DMARD) use

Trial design

396 participants in 2 patient groups

tDMARDs Group

Description:

traditional DMARDs

Treatment:

Drug: tDMARDs

Biologics group

Description:

Biologics used in RA

Treatment:

Drug: biodmards